An investigational drug for advanced multiple myeloma met both of its primary endpoints in a late-stage trial, producing responses in 74 percent of patients whose disease had already resisted three major...
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/ce560758-a9a5-46ff-9cee-f1581ac3fe74)